Vectura to present latest science at Drug Delivery to the Lungs (DDL) 2019

22nd October 2019

Vectura Group plc, a leading inhalation focused CDMO business, will present some of its most recent science in six poster presentations at the 30th Drug Delivery to the Lungs (DDL) Conference in Edinburgh from December 11-13.

DDL is the largest international gathering for those involved in the development of inhaled products, attracting industrial scientists, academics, component suppliers, service providers and regulatory bodies involved in the development and approval of medicines delivered to the respiratory system.

Sandy Munro, VP Pharmaceutical Development at Vectura, presenting at the event, said: “As ever, we look forward to attending the DDL conference. Vectura will be presenting some of its latest science and this speaks to its unique mix of skills and expertise, from formulation development and new technologies to analytics and device development.

"Vectura’s extensive formulation and device teams along with their clinical and regulatory colleagues, are among the best in the industry, making Vectura well placed to support the goals of our customers in the growing inhalation delivery market.”

The global contract development and manufacturing organisation (CDMO) market is large and growing at an annual rate of c. 7%, with data suggesting a shift towards increased outsourcing across the industry (Source: Consolidation of the CDMO industry: opportunities for current players and new entrants, September 2017).

Vectura has a proven track record and is well positioned to capture value within this market by leveraging its core capabilities to support new and existing customers to achieve the optimal formulation and device combination for product development, progression into the clinic and ultimate commercialisation.

Details of poster sessions are as follows:

Title: Development and Verification of a Process to Assess Electrostatic Charge Build-up on an Inhaler
Authors: Sophie Carne and James Henton
Poster board number: 80

Title: Dry Powder Deposition on a Multiple-use Device
Authors: Florence Gower, Karen Western and Ian Davies
Poster board number: 74

Title: Sedimentation or creaming: Assessment of pMDI suspension behaviour
Authors: Sameh Abdrabo, Fritjof Brinkmann, Christine Gouette and Manfred Fischer
Poster board number: 53

Title: Particle size distribution, delivered dose and lung deposition of two mesh nebulisers guiding patients on slow and deep inhalation
Authors: Bernhard Muellinger, Tobias Kolb, Sandy Munro and Anna Ribera
Poster board number: 44

Title: Demonstrating in-vitro equivalence for fixed dose DPI monotherapy products and combinations thereof via spray drying approaches
Authors: Becky Geenan, Malcolm Rothery, Amy Worle & Leszek Roszczyk
Poster board number: 22

Title: Using a combination of In-Silico Lung Deposition Modelling and Secondary Endpoint Data taken from a Phase 3 Clinical Trial in patients with Severe Asthma, to provide evidence that Lung Deposition may be Enhanced when using a Smart Nebuliser instead of a Conventional Nebuliser
Authors: Sandy Munro, Wim Vos, Raulin Surujbally & Benjamin Mignot
Poster board number: 37

Sandy Munro will also chair a session entitled ‘Pat Burnell Young Investigator Award – Past Winners; Where are they now?’ at the conference. Pat was instrumental in the conception of the DDL conference 30 years ago and she was passionate about it being accessible and inclusive to all. The Pat Burnell Award recognises and celebrates her vision and aims to encourage junior researchers from academia or industry to present their work at DDL. At the session Sandy will chair, we hear back from past winners of the Pat Burnell award so we can hear how their careers have developed since winning this prestigious award.

Sandy has had a long association with DDL, and chaired the organising committee for a number of years, up to and beyond the point at which the conference moved to the current Edinburgh venue. He has worked in the inhalation space for over 30 years, the first 20 of which were at GSK, where Sandy was ultimately global Director of Inhalation Science & Technology after which he moved to Vectura. Sandy is also an honorary life member of the Aerosol Society.